Efficacy of Intermittent Occlusion in Amblyopia Treatment

 描述(由申请人提供)：弱视是儿童单眼视力受损的最常见原因，影响总人口的2%-3%。传统上，弱视的治疗方法是用粘性眼罩盖住同伴的眼睛。然而，这种形式的治疗对儿童的依从性很低，因为贴片让人不舒服，并给儿童造成社会耻辱。这项研究的目的是测试一种更适合儿童的新型间歇性咬合疗法(IO Treatment)眼镜的疗效。我们的具体目标是：(1)评估IO疗法治疗严重弱视的疗效；(2)用高科技微型传感器表征IO疗法的客观依从性。这项建议是第一次确定IO疗法作为一种治疗严重弱视的新方法的临床疗效的研究。这项建议的结果将导致：1)更适合儿童和可定制的弱视治疗形式；2)对个人目标依从性的表征，使我们能够制定IO治疗的“以患者为中心的策略”。这一新方向与奥巴马总统在2015年提出的精准医学倡议是一致的。

 DESCRIPTION (provided by applicant): Amblyopia, the most common cause of monocular visual impairment in children, affects 2-3% of the general population. Traditionally, amblyopia is treated using an adhesive eye patch to cover the fellow eye. However, child compliance is low for this form of treatment because the patch is uncomfortable and creates a social stigma for the child. The purpose of this study is to test the efficacy of a more child-friendly novel intermitten occlusion therapy (IO Therapy) glasses. Our Specific Aims: (1) To assess the efficacy of IO Therapy for severe amblyopia; (2) To characterize objective compliance of IO Therapy with a high-tech microsensor. This proposal is the first study to determine the clinical effectiveness of IO Therapy as a novel therapeutic approach for treating severe amblyopia. The findings from this proposal will lead to: 1) a more child-friendly and customizable form of amblyopia treatment; 2) a characterization of individual objective compliance, enabling us to develop a "patient- centered strategy" of IO Therapy. This new direction is consistent with President Obama`s Precision Medicine Initiative in 2015.